Association	O
of	O
Low	O
Ficolin	B:C0217532
-	O
Lectin	O
Pathway	O
Parameters	O
with	O
Cardiac	O
Syndrome	I:C0206064
X	I:C0206064
.	O

Association	O
of	O
Low	O
Ficolin	O
-	O
Lectin	B:C0023206
Pathway	O
Parameters	O
with	O
Cardiac	O
Syndrome	I:C0206064
X	I:C0206064
.	O

Association	O
of	O
Low	O
Ficolin	O
-	O
Lectin	O
Pathway	B:C0312755
Parameters	O
with	O
Cardiac	O
Syndrome	I:C0206064
X	I:C0206064
.	O

Association	O
of	O
Low	O
Ficolin	O
-	O
Lectin	O
Pathway	O
Parameters	O
with	O
Cardiac	B:C0206064
Syndrome	I:C0206064
X	I:C0206064
.	O

In	O
patients	O
with	O
typical	B:C0002962
angina	I:C0002962
pectoris	I:C0002962
,	O
inducible	O
myocardial	O
ischaemia	I:C0151744
and	O
macroscopically	O
normal	O
coronaries	O
(	O
cardiac	O
syndrome	I:C0206064
X	I:C0206064
(	O
cardiac	O
syndrome	I:C0206064
X	I:C0206064
)	O
)	O
,	O
a	O
significantly	O
elevated	O
plasma	O
level	O
of	O
terminal	O
complement	I:C0009545
complex	I:C0009545
(	O
terminal	O
complement	I:C0009545
complex	I:C0009545
)	O
,	O
the	O
common	O
end	O
product	O
of	O
complement	O
activation	I:C0009528
,	O
has	O
been	O
observed	O
without	O
accompanying	O
activation	O
of	O
the	O
classical	O
or	O
the	O
alternative	O
pathways	I:C0009546
.	O

In	O
patients	O
with	O
typical	O
angina	I:C0002962
pectoris	I:C0002962
,	O
inducible	O
myocardial	B:C0151744
ischaemia	I:C0151744
and	O
macroscopically	O
normal	O
coronaries	O
(	O
cardiac	O
syndrome	I:C0206064
X	I:C0206064
(	O
cardiac	O
syndrome	I:C0206064
X	I:C0206064
)	O
)	O
,	O
a	O
significantly	O
elevated	O
plasma	O
level	O
of	O
terminal	O
complement	I:C0009545
complex	I:C0009545
(	O
terminal	O
complement	I:C0009545
complex	I:C0009545
)	O
,	O
the	O
common	O
end	O
product	O
of	O
complement	O
activation	I:C0009528
,	O
has	O
been	O
observed	O
without	O
accompanying	O
activation	O
of	O
the	O
classical	O
or	O
the	O
alternative	O
pathways	I:C0009546
.	O

In	O
patients	O
with	O
typical	O
angina	I:C0002962
pectoris	I:C0002962
,	O
inducible	O
myocardial	O
ischaemia	I:C0151744
and	O
macroscopically	O
normal	O
coronaries	B:C0018787
(	O
cardiac	O
syndrome	I:C0206064
X	I:C0206064
(	O
cardiac	O
syndrome	I:C0206064
X	I:C0206064
)	O
)	O
,	O
a	O
significantly	O
elevated	O
plasma	O
level	O
of	O
terminal	O
complement	I:C0009545
complex	I:C0009545
(	O
terminal	O
complement	I:C0009545
complex	I:C0009545
)	O
,	O
the	O
common	O
end	O
product	O
of	O
complement	O
activation	I:C0009528
,	O
has	O
been	O
observed	O
without	O
accompanying	O
activation	O
of	O
the	O
classical	O
or	O
the	O
alternative	O
pathways	I:C0009546
.	O

In	O
patients	O
with	O
typical	O
angina	I:C0002962
pectoris	I:C0002962
,	O
inducible	O
myocardial	O
ischaemia	I:C0151744
and	O
macroscopically	O
normal	O
coronaries	O
(	O
cardiac	B:C0206064
syndrome	I:C0206064
X	I:C0206064
(	O
cardiac	O
syndrome	I:C0206064
X	I:C0206064
)	O
)	O
,	O
a	O
significantly	O
elevated	O
plasma	O
level	O
of	O
terminal	O
complement	I:C0009545
complex	I:C0009545
(	O
terminal	O
complement	I:C0009545
complex	I:C0009545
)	O
,	O
the	O
common	O
end	O
product	O
of	O
complement	O
activation	I:C0009528
,	O
has	O
been	O
observed	O
without	O
accompanying	O
activation	O
of	O
the	O
classical	O
or	O
the	O
alternative	O
pathways	I:C0009546
.	O

In	O
patients	O
with	O
typical	O
angina	I:C0002962
pectoris	I:C0002962
,	O
inducible	O
myocardial	O
ischaemia	I:C0151744
and	O
macroscopically	O
normal	O
coronaries	O
(	O
cardiac	O
syndrome	I:C0206064
X	I:C0206064
(	O
cardiac	B:C0206064
syndrome	I:C0206064
X	I:C0206064
)	O
)	O
,	O
a	O
significantly	O
elevated	O
plasma	O
level	O
of	O
terminal	O
complement	I:C0009545
complex	I:C0009545
(	O
terminal	O
complement	I:C0009545
complex	I:C0009545
)	O
,	O
the	O
common	O
end	O
product	O
of	O
complement	O
activation	I:C0009528
,	O
has	O
been	O
observed	O
without	O
accompanying	O
activation	O
of	O
the	O
classical	O
or	O
the	O
alternative	O
pathways	I:C0009546
.	O

In	O
patients	O
with	O
typical	O
angina	I:C0002962
pectoris	I:C0002962
,	O
inducible	O
myocardial	O
ischaemia	I:C0151744
and	O
macroscopically	O
normal	O
coronaries	O
(	O
cardiac	O
syndrome	I:C0206064
X	I:C0206064
(	O
cardiac	O
syndrome	I:C0206064
X	I:C0206064
)	O
)	O
,	O
a	O
significantly	O
elevated	O
plasma	B:C0032105
level	O
of	O
terminal	O
complement	I:C0009545
complex	I:C0009545
(	O
terminal	O
complement	I:C0009545
complex	I:C0009545
)	O
,	O
the	O
common	O
end	O
product	O
of	O
complement	O
activation	I:C0009528
,	O
has	O
been	O
observed	O
without	O
accompanying	O
activation	O
of	O
the	O
classical	O
or	O
the	O
alternative	O
pathways	I:C0009546
.	O

In	O
patients	O
with	O
typical	O
angina	I:C0002962
pectoris	I:C0002962
,	O
inducible	O
myocardial	O
ischaemia	I:C0151744
and	O
macroscopically	O
normal	O
coronaries	O
(	O
cardiac	O
syndrome	I:C0206064
X	I:C0206064
(	O
cardiac	O
syndrome	I:C0206064
X	I:C0206064
)	O
)	O
,	O
a	O
significantly	O
elevated	O
plasma	O
level	O
of	O
terminal	B:C0009545
complement	I:C0009545
complex	I:C0009545
(	O
terminal	O
complement	I:C0009545
complex	I:C0009545
)	O
,	O
the	O
common	O
end	O
product	O
of	O
complement	O
activation	I:C0009528
,	O
has	O
been	O
observed	O
without	O
accompanying	O
activation	O
of	O
the	O
classical	O
or	O
the	O
alternative	O
pathways	I:C0009546
.	O

In	O
patients	O
with	O
typical	O
angina	I:C0002962
pectoris	I:C0002962
,	O
inducible	O
myocardial	O
ischaemia	I:C0151744
and	O
macroscopically	O
normal	O
coronaries	O
(	O
cardiac	O
syndrome	I:C0206064
X	I:C0206064
(	O
cardiac	O
syndrome	I:C0206064
X	I:C0206064
)	O
)	O
,	O
a	O
significantly	O
elevated	O
plasma	O
level	O
of	O
terminal	O
complement	I:C0009545
complex	I:C0009545
(	O
terminal	B:C0009545
complement	I:C0009545
complex	I:C0009545
)	O
,	O
the	O
common	O
end	O
product	O
of	O
complement	O
activation	I:C0009528
,	O
has	O
been	O
observed	O
without	O
accompanying	O
activation	O
of	O
the	O
classical	O
or	O
the	O
alternative	O
pathways	I:C0009546
.	O

In	O
patients	O
with	O
typical	O
angina	I:C0002962
pectoris	I:C0002962
,	O
inducible	O
myocardial	O
ischaemia	I:C0151744
and	O
macroscopically	O
normal	O
coronaries	O
(	O
cardiac	O
syndrome	I:C0206064
X	I:C0206064
(	O
cardiac	O
syndrome	I:C0206064
X	I:C0206064
)	O
)	O
,	O
a	O
significantly	O
elevated	O
plasma	O
level	O
of	O
terminal	O
complement	I:C0009545
complex	I:C0009545
(	O
terminal	O
complement	I:C0009545
complex	I:C0009545
)	O
,	O
the	O
common	O
end	O
product	O
of	O
complement	B:C0009528
activation	I:C0009528
,	O
has	O
been	O
observed	O
without	O
accompanying	O
activation	O
of	O
the	O
classical	O
or	O
the	O
alternative	O
pathways	I:C0009546
.	O

In	O
patients	O
with	O
typical	O
angina	I:C0002962
pectoris	I:C0002962
,	O
inducible	O
myocardial	O
ischaemia	I:C0151744
and	O
macroscopically	O
normal	O
coronaries	O
(	O
cardiac	O
syndrome	I:C0206064
X	I:C0206064
(	O
cardiac	O
syndrome	I:C0206064
X	I:C0206064
)	O
)	O
,	O
a	O
significantly	O
elevated	O
plasma	O
level	O
of	O
terminal	O
complement	I:C0009545
complex	I:C0009545
(	O
terminal	O
complement	I:C0009545
complex	I:C0009545
)	O
,	O
the	O
common	O
end	O
product	O
of	O
complement	O
activation	I:C0009528
,	O
has	O
been	O
observed	O
without	O
accompanying	O
activation	O
of	O
the	O
classical	B:C0009547
or	O
the	O
alternative	O
pathways	I:C0009546
.	O

In	O
patients	O
with	O
typical	O
angina	I:C0002962
pectoris	I:C0002962
,	O
inducible	O
myocardial	O
ischaemia	I:C0151744
and	O
macroscopically	O
normal	O
coronaries	O
(	O
cardiac	O
syndrome	I:C0206064
X	I:C0206064
(	O
cardiac	O
syndrome	I:C0206064
X	I:C0206064
)	O
)	O
,	O
a	O
significantly	O
elevated	O
plasma	O
level	O
of	O
terminal	O
complement	I:C0009545
complex	I:C0009545
(	O
terminal	O
complement	I:C0009545
complex	I:C0009545
)	O
,	O
the	O
common	O
end	O
product	O
of	O
complement	O
activation	I:C0009528
,	O
has	O
been	O
observed	O
without	O
accompanying	O
activation	O
of	O
the	O
classical	O
or	O
the	O
alternative	B:C0009546
pathways	I:C0009546
.	O

Therefore	O
,	O
our	O
aim	O
was	O
to	O
clarify	O
the	O
role	O
of	O
the	O
ficolin	B:C0217532
-	O
lectin	O
pathway	O
in	O
cardiac	O
syndrome	I:C0206064
X.	I:C0206064
Eighteen	O
patients	O
with	O
cardiac	O
syndrome	I:C0206064
X	I:C0206064
,	O
37	O
stable	O
angina	O
patients	O
with	O
significant	O
coronary	O
stenosis	I:C0242231
(	O
CHD	O
)	O
and	O
54	O
healthy	O
volunteers	I:C1708335
(	O
HC	O
)	O
were	O
enrolled	O
.	O

Therefore	O
,	O
our	O
aim	O
was	O
to	O
clarify	O
the	O
role	O
of	O
the	O
ficolin	O
-	O
lectin	B:C0023206
pathway	O
in	O
cardiac	O
syndrome	I:C0206064
X.	I:C0206064
Eighteen	O
patients	O
with	O
cardiac	O
syndrome	I:C0206064
X	I:C0206064
,	O
37	O
stable	O
angina	O
patients	O
with	O
significant	O
coronary	O
stenosis	I:C0242231
(	O
CHD	O
)	O
and	O
54	O
healthy	O
volunteers	I:C1708335
(	O
HC	O
)	O
were	O
enrolled	O
.	O

Therefore	O
,	O
our	O
aim	O
was	O
to	O
clarify	O
the	O
role	O
of	O
the	O
ficolin	O
-	O
lectin	O
pathway	B:C0312755
in	O
cardiac	O
syndrome	I:C0206064
X.	I:C0206064
Eighteen	O
patients	O
with	O
cardiac	O
syndrome	I:C0206064
X	I:C0206064
,	O
37	O
stable	O
angina	O
patients	O
with	O
significant	O
coronary	O
stenosis	I:C0242231
(	O
CHD	O
)	O
and	O
54	O
healthy	O
volunteers	I:C1708335
(	O
HC	O
)	O
were	O
enrolled	O
.	O

Therefore	O
,	O
our	O
aim	O
was	O
to	O
clarify	O
the	O
role	O
of	O
the	O
ficolin	O
-	O
lectin	O
pathway	O
in	O
cardiac	B:C0206064
syndrome	I:C0206064
X.	I:C0206064
Eighteen	O
patients	O
with	O
cardiac	O
syndrome	I:C0206064
X	I:C0206064
,	O
37	O
stable	O
angina	O
patients	O
with	O
significant	O
coronary	O
stenosis	I:C0242231
(	O
CHD	O
)	O
and	O
54	O
healthy	O
volunteers	I:C1708335
(	O
HC	O
)	O
were	O
enrolled	O
.	O

Therefore	O
,	O
our	O
aim	O
was	O
to	O
clarify	O
the	O
role	O
of	O
the	O
ficolin	O
-	O
lectin	O
pathway	O
in	O
cardiac	O
syndrome	I:C0206064
X.	I:C0206064
Eighteen	O
patients	O
with	O
cardiac	B:C0206064
syndrome	I:C0206064
X	I:C0206064
,	O
37	O
stable	O
angina	O
patients	O
with	O
significant	O
coronary	O
stenosis	I:C0242231
(	O
CHD	O
)	O
and	O
54	O
healthy	O
volunteers	I:C1708335
(	O
HC	O
)	O
were	O
enrolled	O
.	O

Therefore	O
,	O
our	O
aim	O
was	O
to	O
clarify	O
the	O
role	O
of	O
the	O
ficolin	O
-	O
lectin	O
pathway	O
in	O
cardiac	O
syndrome	I:C0206064
X.	I:C0206064
Eighteen	O
patients	O
with	O
cardiac	O
syndrome	I:C0206064
X	I:C0206064
,	O
37	O
stable	O
angina	B:C0002962
patients	O
with	O
significant	O
coronary	O
stenosis	I:C0242231
(	O
CHD	O
)	O
and	O
54	O
healthy	O
volunteers	I:C1708335
(	O
HC	O
)	O
were	O
enrolled	O
.	O

Therefore	O
,	O
our	O
aim	O
was	O
to	O
clarify	O
the	O
role	O
of	O
the	O
ficolin	O
-	O
lectin	O
pathway	O
in	O
cardiac	O
syndrome	I:C0206064
X.	I:C0206064
Eighteen	O
patients	O
with	O
cardiac	O
syndrome	I:C0206064
X	I:C0206064
,	O
37	O
stable	O
angina	O
patients	O
with	O
significant	O
coronary	B:C0242231
stenosis	I:C0242231
(	O
CHD	O
)	O
and	O
54	O
healthy	O
volunteers	I:C1708335
(	O
HC	O
)	O
were	O
enrolled	O
.	O

Therefore	O
,	O
our	O
aim	O
was	O
to	O
clarify	O
the	O
role	O
of	O
the	O
ficolin	O
-	O
lectin	O
pathway	O
in	O
cardiac	O
syndrome	I:C0206064
X.	I:C0206064
Eighteen	O
patients	O
with	O
cardiac	O
syndrome	I:C0206064
X	I:C0206064
,	O
37	O
stable	O
angina	O
patients	O
with	O
significant	O
coronary	O
stenosis	I:C0242231
(	O
CHD	B:C0242231
)	O
and	O
54	O
healthy	O
volunteers	I:C1708335
(	O
HC	O
)	O
were	O
enrolled	O
.	O

Therefore	O
,	O
our	O
aim	O
was	O
to	O
clarify	O
the	O
role	O
of	O
the	O
ficolin	O
-	O
lectin	O
pathway	O
in	O
cardiac	O
syndrome	I:C0206064
X.	I:C0206064
Eighteen	O
patients	O
with	O
cardiac	O
syndrome	I:C0206064
X	I:C0206064
,	O
37	O
stable	O
angina	O
patients	O
with	O
significant	O
coronary	O
stenosis	I:C0242231
(	O
CHD	O
)	O
and	O
54	O
healthy	B:C1708335
volunteers	I:C1708335
(	O
HC	O
)	O
were	O
enrolled	O
.	O

Therefore	O
,	O
our	O
aim	O
was	O
to	O
clarify	O
the	O
role	O
of	O
the	O
ficolin	O
-	O
lectin	O
pathway	O
in	O
cardiac	O
syndrome	I:C0206064
X.	I:C0206064
Eighteen	O
patients	O
with	O
cardiac	O
syndrome	I:C0206064
X	I:C0206064
,	O
37	O
stable	O
angina	O
patients	O
with	O
significant	O
coronary	O
stenosis	I:C0242231
(	O
CHD	O
)	O
and	O
54	O
healthy	O
volunteers	I:C1708335
(	O
HC	B:C1708335
)	O
were	O
enrolled	O
.	O

Therefore	O
,	O
our	O
aim	O
was	O
to	O
clarify	O
the	O
role	O
of	O
the	O
ficolin	O
-	O
lectin	O
pathway	O
in	O
cardiac	O
syndrome	I:C0206064
X.	I:C0206064
Eighteen	O
patients	O
with	O
cardiac	O
syndrome	I:C0206064
X	I:C0206064
,	O
37	O
stable	O
angina	O
patients	O
with	O
significant	O
coronary	O
stenosis	I:C0242231
(	O
CHD	O
)	O
and	O
54	O
healthy	O
volunteers	I:C1708335
(	O
HC	O
)	O
were	O
enrolled	B:C4041024
.	O

Serum	B:C0229671
levels	O
of	O
ficolin	O
-	I:C0753749
2	I:C0753749
and	O
ficolin	O
-	I:C1431109
3	I:C1431109
,	O
ficolin	O
-	I:C1431109
3	I:C1431109
/	O
MASP	O
-	I:C0537643
2	I:C0537643
complex	O
and	O
ficolin	O
-	I:C1431109
3	I:C1431109
-	O
mediated	O
terminal	O
complement	I:C0009545
complex	I:C0009545
deposition	O
(	O
FCN3	O
-	O
terminal	O
complement	I:C0009545
complex	I:C0009545
)	O
were	O
determined	O
.	O

Serum	O
levels	O
of	O
ficolin	B:C0753749
-	I:C0753749
2	I:C0753749
and	O
ficolin	O
-	I:C1431109
3	I:C1431109
,	O
ficolin	O
-	I:C1431109
3	I:C1431109
/	O
MASP	O
-	I:C0537643
2	I:C0537643
complex	O
and	O
ficolin	O
-	I:C1431109
3	I:C1431109
-	O
mediated	O
terminal	O
complement	I:C0009545
complex	I:C0009545
deposition	O
(	O
FCN3	O
-	O
terminal	O
complement	I:C0009545
complex	I:C0009545
)	O
were	O
determined	O
.	O

Serum	O
levels	O
of	O
ficolin	O
-	I:C0753749
2	I:C0753749
and	O
ficolin	B:C1431109
-	I:C1431109
3	I:C1431109
,	O
ficolin	O
-	I:C1431109
3	I:C1431109
/	O
MASP	O
-	I:C0537643
2	I:C0537643
complex	O
and	O
ficolin	O
-	I:C1431109
3	I:C1431109
-	O
mediated	O
terminal	O
complement	I:C0009545
complex	I:C0009545
deposition	O
(	O
FCN3	O
-	O
terminal	O
complement	I:C0009545
complex	I:C0009545
)	O
were	O
determined	O
.	O

Serum	O
levels	O
of	O
ficolin	O
-	I:C0753749
2	I:C0753749
and	O
ficolin	O
-	I:C1431109
3	I:C1431109
,	O
ficolin	B:C1431109
-	I:C1431109
3	I:C1431109
/	O
MASP	O
-	I:C0537643
2	I:C0537643
complex	O
and	O
ficolin	O
-	I:C1431109
3	I:C1431109
-	O
mediated	O
terminal	O
complement	I:C0009545
complex	I:C0009545
deposition	O
(	O
FCN3	O
-	O
terminal	O
complement	I:C0009545
complex	I:C0009545
)	O
were	O
determined	O
.	O

Serum	O
levels	O
of	O
ficolin	O
-	I:C0753749
2	I:C0753749
and	O
ficolin	O
-	I:C1431109
3	I:C1431109
,	O
ficolin	O
-	I:C1431109
3	I:C1431109
/	O
MASP	B:C0537643
-	I:C0537643
2	I:C0537643
complex	O
and	O
ficolin	O
-	I:C1431109
3	I:C1431109
-	O
mediated	O
terminal	O
complement	I:C0009545
complex	I:C0009545
deposition	O
(	O
FCN3	O
-	O
terminal	O
complement	I:C0009545
complex	I:C0009545
)	O
were	O
determined	O
.	O

Serum	O
levels	O
of	O
ficolin	O
-	I:C0753749
2	I:C0753749
and	O
ficolin	O
-	I:C1431109
3	I:C1431109
,	O
ficolin	O
-	I:C1431109
3	I:C1431109
/	O
MASP	O
-	I:C0537643
2	I:C0537643
complex	B:C1180347
and	O
ficolin	O
-	I:C1431109
3	I:C1431109
-	O
mediated	O
terminal	O
complement	I:C0009545
complex	I:C0009545
deposition	O
(	O
FCN3	O
-	O
terminal	O
complement	I:C0009545
complex	I:C0009545
)	O
were	O
determined	O
.	O

Serum	O
levels	O
of	O
ficolin	O
-	I:C0753749
2	I:C0753749
and	O
ficolin	O
-	I:C1431109
3	I:C1431109
,	O
ficolin	O
-	I:C1431109
3	I:C1431109
/	O
MASP	O
-	I:C0537643
2	I:C0537643
complex	O
and	O
ficolin	B:C1431109
-	I:C1431109
3	I:C1431109
-	O
mediated	O
terminal	O
complement	I:C0009545
complex	I:C0009545
deposition	O
(	O
FCN3	O
-	O
terminal	O
complement	I:C0009545
complex	I:C0009545
)	O
were	O
determined	O
.	O

Serum	O
levels	O
of	O
ficolin	O
-	I:C0753749
2	I:C0753749
and	O
ficolin	O
-	I:C1431109
3	I:C1431109
,	O
ficolin	O
-	I:C1431109
3	I:C1431109
/	O
MASP	O
-	I:C0537643
2	I:C0537643
complex	O
and	O
ficolin	O
-	I:C1431109
3	I:C1431109
-	O
mediated	O
terminal	B:C0009545
complement	I:C0009545
complex	I:C0009545
deposition	O
(	O
FCN3	O
-	O
terminal	O
complement	I:C0009545
complex	I:C0009545
)	O
were	O
determined	O
.	O

Serum	O
levels	O
of	O
ficolin	O
-	I:C0753749
2	I:C0753749
and	O
ficolin	O
-	I:C1431109
3	I:C1431109
,	O
ficolin	O
-	I:C1431109
3	I:C1431109
/	O
MASP	O
-	I:C0537643
2	I:C0537643
complex	O
and	O
ficolin	O
-	I:C1431109
3	I:C1431109
-	O
mediated	O
terminal	O
complement	I:C0009545
complex	I:C0009545
deposition	O
(	O
FCN3	B:C1431109
-	O
terminal	O
complement	I:C0009545
complex	I:C0009545
)	O
were	O
determined	O
.	O

Serum	O
levels	O
of	O
ficolin	O
-	I:C0753749
2	I:C0753749
and	O
ficolin	O
-	I:C1431109
3	I:C1431109
,	O
ficolin	O
-	I:C1431109
3	I:C1431109
/	O
MASP	O
-	I:C0537643
2	I:C0537643
complex	O
and	O
ficolin	O
-	I:C1431109
3	I:C1431109
-	O
mediated	O
terminal	O
complement	I:C0009545
complex	I:C0009545
deposition	O
(	O
FCN3	O
-	O
terminal	B:C0009545
complement	I:C0009545
complex	I:C0009545
)	O
were	O
determined	O
.	O

Plasma	B:C0032105
level	O
of	O
terminal	O
complement	I:C0009545
complex	I:C0009545
was	O
significantly	O
higher	O
in	O
the	O
CSX	O
than	O
in	O
the	O
HC	O
or	O
CHD	O
group	O
(	O
5.45	O
versus	O
1.30	O
versus	O
2.04	O
AU	O
/	O
ml	O
,	O
P	O
<	O
0.001	O
)	O
.	O

Plasma	O
level	O
of	O
terminal	B:C0009545
complement	I:C0009545
complex	I:C0009545
was	O
significantly	O
higher	O
in	O
the	O
CSX	O
than	O
in	O
the	O
HC	O
or	O
CHD	O
group	O
(	O
5.45	O
versus	O
1.30	O
versus	O
2.04	O
AU	O
/	O
ml	O
,	O
P	O
<	O
0.001	O
)	O
.	O

Plasma	O
level	O
of	O
terminal	O
complement	I:C0009545
complex	I:C0009545
was	O
significantly	O
higher	O
in	O
the	O
CSX	O
than	O
in	O
the	O
HC	B:C1708335
or	O
CHD	O
group	O
(	O
5.45	O
versus	O
1.30	O
versus	O
2.04	O
AU	O
/	O
ml	O
,	O
P	O
<	O
0.001	O
)	O
.	O

Serum	B:C0229671
levels	O
of	O
ficolin	O
-	I:C0753749
2	I:C0753749
and	O
ficolin	O
-	I:C1431109
3	I:C1431109
were	O
significantly	O
lower	O
in	O
the	O
CSX	O
compared	O
to	O
the	O
HC	O
or	O
CHD	O
group	O
(	O
3.60	O
versus	O
5.80	O
or	O
5.20	O
μg/ml	O
,	O
P	O
<	O
0.05	O
;	O
17.80	O
versus	O
24.10	O
or	O
26.80	O
μg/ml	O
,	O
P	O
<	O
0.05	O
)	O
.	O

Serum	O
levels	O
of	O
ficolin	B:C0753749
-	I:C0753749
2	I:C0753749
and	O
ficolin	O
-	I:C1431109
3	I:C1431109
were	O
significantly	O
lower	O
in	O
the	O
CSX	O
compared	O
to	O
the	O
HC	O
or	O
CHD	O
group	O
(	O
3.60	O
versus	O
5.80	O
or	O
5.20	O
μg/ml	O
,	O
P	O
<	O
0.05	O
;	O
17.80	O
versus	O
24.10	O
or	O
26.80	O
μg/ml	O
,	O
P	O
<	O
0.05	O
)	O
.	O

Serum	O
levels	O
of	O
ficolin	O
-	I:C0753749
2	I:C0753749
and	O
ficolin	B:C1431109
-	I:C1431109
3	I:C1431109
were	O
significantly	O
lower	O
in	O
the	O
CSX	O
compared	O
to	O
the	O
HC	O
or	O
CHD	O
group	O
(	O
3.60	O
versus	O
5.80	O
or	O
5.20	O
μg/ml	O
,	O
P	O
<	O
0.05	O
;	O
17.80	O
versus	O
24.10	O
or	O
26.80	O
μg/ml	O
,	O
P	O
<	O
0.05	O
)	O
.	O

Serum	O
levels	O
of	O
ficolin	O
-	I:C0753749
2	I:C0753749
and	O
ficolin	O
-	I:C1431109
3	I:C1431109
were	O
significantly	O
lower	O
in	O
the	O
CSX	O
compared	O
to	O
the	O
HC	B:C1708335
or	O
CHD	O
group	O
(	O
3.60	O
versus	O
5.80	O
or	O
5.20	O
μg/ml	O
,	O
P	O
<	O
0.05	O
;	O
17.80	O
versus	O
24.10	O
or	O
26.80	O
μg/ml	O
,	O
P	O
<	O
0.05	O
)	O
.	O

The	O
ficolin	B:C1431109
-	I:C1431109
3	I:C1431109
/	O
MASP	O
-	I:C0537643
2	I:C0537643
complex	O
was	O
significantly	O
lower	O
in	O
the	O
cardiac	O
syndrome	I:C0206064
X	I:C0206064
group	O
compared	O
to	O
the	O
HC	O
group	I:C1708335
(	O
92.90	O
versus	O
144.90	O
AU	O
/	O
ml	O
,	O
P	O
=	O
0.006	O
)	O
.	O

The	O
ficolin	O
-	I:C1431109
3	I:C1431109
/	O
MASP	B:C0537643
-	I:C0537643
2	I:C0537643
complex	O
was	O
significantly	O
lower	O
in	O
the	O
cardiac	O
syndrome	I:C0206064
X	I:C0206064
group	O
compared	O
to	O
the	O
HC	O
group	I:C1708335
(	O
92.90	O
versus	O
144.90	O
AU	O
/	O
ml	O
,	O
P	O
=	O
0.006	O
)	O
.	O

The	O
ficolin	O
-	I:C1431109
3	I:C1431109
/	O
MASP	O
-	I:C0537643
2	I:C0537643
complex	B:C1180347
was	O
significantly	O
lower	O
in	O
the	O
cardiac	O
syndrome	I:C0206064
X	I:C0206064
group	O
compared	O
to	O
the	O
HC	O
group	I:C1708335
(	O
92.90	O
versus	O
144.90	O
AU	O
/	O
ml	O
,	O
P	O
=	O
0.006	O
)	O
.	O

The	O
ficolin	O
-	I:C1431109
3	I:C1431109
/	O
MASP	O
-	I:C0537643
2	I:C0537643
complex	O
was	O
significantly	O
lower	O
in	O
the	O
cardiac	B:C0206064
syndrome	I:C0206064
X	I:C0206064
group	O
compared	O
to	O
the	O
HC	O
group	I:C1708335
(	O
92.90	O
versus	O
144.90	O
AU	O
/	O
ml	O
,	O
P	O
=	O
0.006	O
)	O
.	O

The	O
ficolin	O
-	I:C1431109
3	I:C1431109
/	O
MASP	O
-	I:C0537643
2	I:C0537643
complex	O
was	O
significantly	O
lower	O
in	O
the	O
cardiac	O
syndrome	I:C0206064
X	I:C0206064
group	O
compared	O
to	O
the	O
HC	B:C1708335
group	I:C1708335
(	O
92.90	O
versus	O
144.90	O
AU	O
/	O
ml	O
,	O
P	O
=	O
0.006	O
)	O
.	O

FCN3	B:C1431109
-	O
terminal	O
complement	I:C0009545
complex	I:C0009545
deposition	O
was	O
significantly	O
lower	O
in	O
the	O
cardiac	O
syndrome	I:C0206064
X	I:C0206064
group	O
compared	O
to	O
the	O
HC	O
and	O
CHD	O
groups	O
(	O
67.8	O
%	O
versus	O
143.3	O
%	O
or	O
159.7	O
%	O
,	O
P	O
<	O
0.05	O
)	O
.	O

FCN3	O
-	O
terminal	B:C0009545
complement	I:C0009545
complex	I:C0009545
deposition	O
was	O
significantly	O
lower	O
in	O
the	O
cardiac	O
syndrome	I:C0206064
X	I:C0206064
group	O
compared	O
to	O
the	O
HC	O
and	O
CHD	O
groups	O
(	O
67.8	O
%	O
versus	O
143.3	O
%	O
or	O
159.7	O
%	O
,	O
P	O
<	O
0.05	O
)	O
.	O

FCN3	O
-	O
terminal	O
complement	I:C0009545
complex	I:C0009545
deposition	O
was	O
significantly	O
lower	O
in	O
the	O
cardiac	B:C0206064
syndrome	I:C0206064
X	I:C0206064
group	O
compared	O
to	O
the	O
HC	O
and	O
CHD	O
groups	O
(	O
67.8	O
%	O
versus	O
143.3	O
%	O
or	O
159.7	O
%	O
,	O
P	O
<	O
0.05	O
)	O
.	O

FCN3	O
-	O
terminal	O
complement	I:C0009545
complex	I:C0009545
deposition	O
was	O
significantly	O
lower	O
in	O
the	O
cardiac	O
syndrome	I:C0206064
X	I:C0206064
group	O
compared	O
to	O
the	O
HC	B:C1708335
and	O
CHD	O
groups	O
(	O
67.8	O
%	O
versus	O
143.3	O
%	O
or	O
159.7	O
%	O
,	O
P	O
<	O
0.05	O
)	O
.	O

In	O
the	O
cardiac	B:C0206064
syndrome	I:C0206064
X	I:C0206064
group	O
,	O
a	O
significant	O
correlation	O
was	O
found	O
between	O
terminal	O
complement	I:C0009545
complex	I:C0009545
and	O
FCN3	O
-	O
terminal	O
complement	I:C0009545
complex	I:C0009545
level	O
(	O
r	O
=	O
0.507	O
,	O
P	O
=	O
0.032	O
)	O
and	O
between	O
ficolin	O
-	I:C1431109
3	I:C1431109
/	O
MASP	O
-	I:C0537643
2	I:C0537643
complex	O
level	O
and	O
FCN3	O
-	O
terminal	O
complement	I:C0009545
complex	I:C0009545
deposition	O
(	O
r	O
=	O
0.651	O
,	O
P	O
=	O
0.003	O
)	O
.	O

In	O
the	O
cardiac	O
syndrome	I:C0206064
X	I:C0206064
group	O
,	O
a	O
significant	O
correlation	O
was	O
found	O
between	O
terminal	B:C0009545
complement	I:C0009545
complex	I:C0009545
and	O
FCN3	O
-	O
terminal	O
complement	I:C0009545
complex	I:C0009545
level	O
(	O
r	O
=	O
0.507	O
,	O
P	O
=	O
0.032	O
)	O
and	O
between	O
ficolin	O
-	I:C1431109
3	I:C1431109
/	O
MASP	O
-	I:C0537643
2	I:C0537643
complex	O
level	O
and	O
FCN3	O
-	O
terminal	O
complement	I:C0009545
complex	I:C0009545
deposition	O
(	O
r	O
=	O
0.651	O
,	O
P	O
=	O
0.003	O
)	O
.	O

In	O
the	O
cardiac	O
syndrome	I:C0206064
X	I:C0206064
group	O
,	O
a	O
significant	O
correlation	O
was	O
found	O
between	O
terminal	O
complement	I:C0009545
complex	I:C0009545
and	O
FCN3	B:C1431109
-	O
terminal	O
complement	I:C0009545
complex	I:C0009545
level	O
(	O
r	O
=	O
0.507	O
,	O
P	O
=	O
0.032	O
)	O
and	O
between	O
ficolin	O
-	I:C1431109
3	I:C1431109
/	O
MASP	O
-	I:C0537643
2	I:C0537643
complex	O
level	O
and	O
FCN3	O
-	O
terminal	O
complement	I:C0009545
complex	I:C0009545
deposition	O
(	O
r	O
=	O
0.651	O
,	O
P	O
=	O
0.003	O
)	O
.	O

In	O
the	O
cardiac	O
syndrome	I:C0206064
X	I:C0206064
group	O
,	O
a	O
significant	O
correlation	O
was	O
found	O
between	O
terminal	O
complement	I:C0009545
complex	I:C0009545
and	O
FCN3	O
-	O
terminal	B:C0009545
complement	I:C0009545
complex	I:C0009545
level	O
(	O
r	O
=	O
0.507	O
,	O
P	O
=	O
0.032	O
)	O
and	O
between	O
ficolin	O
-	I:C1431109
3	I:C1431109
/	O
MASP	O
-	I:C0537643
2	I:C0537643
complex	O
level	O
and	O
FCN3	O
-	O
terminal	O
complement	I:C0009545
complex	I:C0009545
deposition	O
(	O
r	O
=	O
0.651	O
,	O
P	O
=	O
0.003	O
)	O
.	O

In	O
the	O
cardiac	O
syndrome	I:C0206064
X	I:C0206064
group	O
,	O
a	O
significant	O
correlation	O
was	O
found	O
between	O
terminal	O
complement	I:C0009545
complex	I:C0009545
and	O
FCN3	O
-	O
terminal	O
complement	I:C0009545
complex	I:C0009545
level	O
(	O
r	O
=	O
0.507	O
,	O
P	O
=	O
0.032	O
)	O
and	O
between	O
ficolin	B:C1431109
-	I:C1431109
3	I:C1431109
/	O
MASP	O
-	I:C0537643
2	I:C0537643
complex	O
level	O
and	O
FCN3	O
-	O
terminal	O
complement	I:C0009545
complex	I:C0009545
deposition	O
(	O
r	O
=	O
0.651	O
,	O
P	O
=	O
0.003	O
)	O
.	O

In	O
the	O
cardiac	O
syndrome	I:C0206064
X	I:C0206064
group	O
,	O
a	O
significant	O
correlation	O
was	O
found	O
between	O
terminal	O
complement	I:C0009545
complex	I:C0009545
and	O
FCN3	O
-	O
terminal	O
complement	I:C0009545
complex	I:C0009545
level	O
(	O
r	O
=	O
0.507	O
,	O
P	O
=	O
0.032	O
)	O
and	O
between	O
ficolin	O
-	I:C1431109
3	I:C1431109
/	O
MASP	B:C0537643
-	I:C0537643
2	I:C0537643
complex	O
level	O
and	O
FCN3	O
-	O
terminal	O
complement	I:C0009545
complex	I:C0009545
deposition	O
(	O
r	O
=	O
0.651	O
,	O
P	O
=	O
0.003	O
)	O
.	O

In	O
the	O
cardiac	O
syndrome	I:C0206064
X	I:C0206064
group	O
,	O
a	O
significant	O
correlation	O
was	O
found	O
between	O
terminal	O
complement	I:C0009545
complex	I:C0009545
and	O
FCN3	O
-	O
terminal	O
complement	I:C0009545
complex	I:C0009545
level	O
(	O
r	O
=	O
0.507	O
,	O
P	O
=	O
0.032	O
)	O
and	O
between	O
ficolin	O
-	I:C1431109
3	I:C1431109
/	O
MASP	O
-	I:C0537643
2	I:C0537643
complex	B:C1180347
level	O
and	O
FCN3	O
-	O
terminal	O
complement	I:C0009545
complex	I:C0009545
deposition	O
(	O
r	O
=	O
0.651	O
,	O
P	O
=	O
0.003	O
)	O
.	O

In	O
the	O
cardiac	O
syndrome	I:C0206064
X	I:C0206064
group	O
,	O
a	O
significant	O
correlation	O
was	O
found	O
between	O
terminal	O
complement	I:C0009545
complex	I:C0009545
and	O
FCN3	O
-	O
terminal	O
complement	I:C0009545
complex	I:C0009545
level	O
(	O
r	O
=	O
0.507	O
,	O
P	O
=	O
0.032	O
)	O
and	O
between	O
ficolin	O
-	I:C1431109
3	I:C1431109
/	O
MASP	O
-	I:C0537643
2	I:C0537643
complex	O
level	O
and	O
FCN3	B:C1431109
-	O
terminal	O
complement	I:C0009545
complex	I:C0009545
deposition	O
(	O
r	O
=	O
0.651	O
,	O
P	O
=	O
0.003	O
)	O
.	O

In	O
the	O
cardiac	O
syndrome	I:C0206064
X	I:C0206064
group	O
,	O
a	O
significant	O
correlation	O
was	O
found	O
between	O
terminal	O
complement	I:C0009545
complex	I:C0009545
and	O
FCN3	O
-	O
terminal	O
complement	I:C0009545
complex	I:C0009545
level	O
(	O
r	O
=	O
0.507	O
,	O
P	O
=	O
0.032	O
)	O
and	O
between	O
ficolin	O
-	I:C1431109
3	I:C1431109
/	O
MASP	O
-	I:C0537643
2	I:C0537643
complex	O
level	O
and	O
FCN3	O
-	O
terminal	B:C0009545
complement	I:C0009545
complex	I:C0009545
deposition	O
(	O
r	O
=	O
0.651	O
,	O
P	O
=	O
0.003	O
)	O
.	O

In	O
conclusion	O
,	O
in	O
patients	O
with	O
typical	B:C1998435
angina	I:C1998435
and	O
myocardial	O
ischaemia	I:C0151744
despite	O
macroscopically	O
normal	O
coronary	I:C1299335
arteries	I:C1299335
,	O
low	O
levels	O
of	O
several	O
lectin	O
pathway	O
parameters	O
were	O
observed	O
,	O
indicating	O
complement	O
activation	I:C0009528
and	O
consumption	O
.	O

In	O
conclusion	O
,	O
in	O
patients	O
with	O
typical	O
angina	I:C1998435
and	O
myocardial	B:C0151744
ischaemia	I:C0151744
despite	O
macroscopically	O
normal	O
coronary	I:C1299335
arteries	I:C1299335
,	O
low	O
levels	O
of	O
several	O
lectin	O
pathway	O
parameters	O
were	O
observed	O
,	O
indicating	O
complement	O
activation	I:C0009528
and	O
consumption	O
.	O

In	O
conclusion	O
,	O
in	O
patients	O
with	O
typical	O
angina	I:C1998435
and	O
myocardial	O
ischaemia	I:C0151744
despite	O
macroscopically	O
normal	B:C1299335
coronary	I:C1299335
arteries	I:C1299335
,	O
low	O
levels	O
of	O
several	O
lectin	O
pathway	O
parameters	O
were	O
observed	O
,	O
indicating	O
complement	O
activation	I:C0009528
and	O
consumption	O
.	O

In	O
conclusion	O
,	O
in	O
patients	O
with	O
typical	O
angina	I:C1998435
and	O
myocardial	O
ischaemia	I:C0151744
despite	O
macroscopically	O
normal	O
coronary	I:C1299335
arteries	I:C1299335
,	O
low	O
levels	O
of	O
several	O
lectin	B:C0023206
pathway	O
parameters	O
were	O
observed	O
,	O
indicating	O
complement	O
activation	I:C0009528
and	O
consumption	O
.	O

In	O
conclusion	O
,	O
in	O
patients	O
with	O
typical	O
angina	I:C1998435
and	O
myocardial	O
ischaemia	I:C0151744
despite	O
macroscopically	O
normal	O
coronary	I:C1299335
arteries	I:C1299335
,	O
low	O
levels	O
of	O
several	O
lectin	O
pathway	B:C0312755
parameters	O
were	O
observed	O
,	O
indicating	O
complement	O
activation	I:C0009528
and	O
consumption	O
.	O

In	O
conclusion	O
,	O
in	O
patients	O
with	O
typical	O
angina	I:C1998435
and	O
myocardial	O
ischaemia	I:C0151744
despite	O
macroscopically	O
normal	O
coronary	I:C1299335
arteries	I:C1299335
,	O
low	O
levels	O
of	O
several	O
lectin	O
pathway	O
parameters	O
were	O
observed	O
,	O
indicating	O
complement	B:C0009528
activation	I:C0009528
and	O
consumption	O
.	O

In	O
conclusion	O
,	O
in	O
patients	O
with	O
typical	O
angina	I:C1998435
and	O
myocardial	O
ischaemia	I:C0151744
despite	O
macroscopically	O
normal	O
coronary	I:C1299335
arteries	I:C1299335
,	O
low	O
levels	O
of	O
several	O
lectin	O
pathway	O
parameters	O
were	O
observed	O
,	O
indicating	O
complement	O
activation	I:C0009528
and	O
consumption	B:C1947907
.	O

Complement	B:C0009528
activation	I:C0009528
through	O
the	O
ficolin	O
-	O
lectin	O
pathway	O
might	O
play	O
a	O
role	O
in	O
the	O
complex	O
pathomechanism	O
of	O
cardiac	O
syndrome	I:C0206064
X	I:C0206064
.	O

Complement	O
activation	I:C0009528
through	O
the	O
ficolin	B:C0217532
-	O
lectin	O
pathway	O
might	O
play	O
a	O
role	O
in	O
the	O
complex	O
pathomechanism	O
of	O
cardiac	O
syndrome	I:C0206064
X	I:C0206064
.	O

Complement	O
activation	I:C0009528
through	O
the	O
ficolin	O
-	O
lectin	B:C0023206
pathway	O
might	O
play	O
a	O
role	O
in	O
the	O
complex	O
pathomechanism	O
of	O
cardiac	O
syndrome	I:C0206064
X	I:C0206064
.	O

Complement	O
activation	I:C0009528
through	O
the	O
ficolin	O
-	O
lectin	O
pathway	B:C0312755
might	O
play	O
a	O
role	O
in	O
the	O
complex	O
pathomechanism	O
of	O
cardiac	O
syndrome	I:C0206064
X	I:C0206064
.	O

Complement	O
activation	I:C0009528
through	O
the	O
ficolin	O
-	O
lectin	O
pathway	O
might	O
play	O
a	O
role	O
in	O
the	O
complex	O
pathomechanism	O
of	O
cardiac	B:C0206064
syndrome	I:C0206064
X	I:C0206064
.	O

